David Walter Pignolet

Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million.

Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom.

Part of Bristol Myers Squibb Co., Celgene SRL (Belgium) is a Belgian company that engages in research and development on biotechnology. The company is based in Watermaal-Bosvoorde, Belgium. The CEOs are Katherine Reynolds Kelly, David Walter Pignolet. The company was founded in 2006.

Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France.